NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.

The firm has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same offering price per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.